Table 2.
Cardiovascular risk characteristics in primary prevention T2DM groups in SGLT2i CVOT.
CVOT/SGLT2i | Population characteristics in primary prevention group | %/n of patients in primary prevention group |
---|---|---|
DECLARE-TIMI 58 [32]/Dapagliflozin | Adults with T2DM (HbA1c ≥6.5%) and no known CVD and ≥2 CV risk factors in addition to T2DM, defined as:
|
59.4%, 10186 |
CANVAS program [30]/Canagliflozin | Adults with T2DM (HbA1c: ≥7.0% to ≤10.5%) and the following risk factors:
|
34%, 3486 |
CREDENCE [31]/Canagliflozina | Adults aged ≥30 years with T2DM (HbA1c ≥6.5% to ≤12.0%) and the following:
|
49.6%, 2181 |
ASCVD: atherosclerotic cardiovascular disease, CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration equation, CV: cardiovascular, CVD: cardiovascular disease, CVOT: cardiovascular outcome trials, DBP: diastolic blood pressure, eGFR: estimated glomerular filtration rate, HbA1c: glycated hemoglobin, HDL-C: high-density lipoprotein cholesterol, LDL-C: low density lipoprotein-cholesterol, SBP: systolic blood pressure, SGLT2i: sodium-glucose co-transporter 2 inhibitor, T2DM: type 2 diabetes mellitus, UACR: urinary albumin:creatinine ratio.
In CREDENCE trial, the inclusion criteria for patients with CVD and patients at CV risk were not separately listed.